Carbamazepine, an anticonvulsant and a mood-stabilizing drug, is the main cause of the Stevens-Johnson syndrome (SJS) and its related disease, toxic epidermal necrolysis (TEN), in Southeast Asian countries. Carbamazepine-induced SJS-TEN is strongly associated with the HLA-B*1502 allele. We sought to prevent carbamazepine-induced SJS-TEN by using HLA-B*1502 screening to prospectively identify subjects at genetic risk for the condition.
[ hide abstract ]
|Prospective screening for HLA-B*15:02 significantly decreased the incidence of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) (p<0.001)|
|Prospective screening||Historical incidence|
|HLA-B*15:02 positive patients excluded from treatment, HLA-B*15:02 negative patients received carbamazepine||Expected number of (SJS/TEN) cases given historical incidence|
|0 patients developed SJS/TEN||10 patients estimated to develop SJS/TEN based on historical incidence|